Nordic Bioproducts Group Receives Pharmaceutical Industry’s EXCiPACT™ Certification for MCC Production at Lappeenranta Facility
The Finnish company’s new factory has received the prestigious certification after being thoroughly audited by a recognized international entity. Nordic Bioproducts Group’s product offers the perfect solution for the pharmaceutical industry, combining quality and sustainability.
Espoo, Finland [26.6.2024] – Nordic Bioproducts Group today announces that its new manufacturing factory in Lappeenranta, Finland, has received the prestigious EXCiPACT™ certification for the production of microcrystalline cellulose (MCC). This certification is a testament to its unwavering commitment to exceeding industry standards in quality, safety, and excellence in production.
EXCiPACT™ is an independent, not-for-profit association that provides management oversight for the third-party certification of manufacturers, suppliers, and distributors of pharmaceutical excipients worldwide. EXCiPACT™ selects independent, third-party accredited certification bodies that employ ISO 9001 qualified auditors who also meet EXCiPACT™ auditor competency requirements. This rigorous, independent certification system ensures compliance with GMP (Good Manufacturing Practice) and/or GDP (Good Distribution Practice) standards.
The company received the certification from ACT, one of EXCiPACT™’s internationally recognized certification bodies, following a comprehensive audit. The Certificate demonstrates that its site manufactures and distributes Microcrystaline Cellulose (MCC-AaltoCellTM) for the pharmaceutical industry according to the 2021 EXCiPACT Certification Standard for Pharmaceutical Excipient Suppliers.
In addition to the EXCiPACT™ certification, findings of an independent third-party LCA indicate that Nordic Bioproducts Group’s process also achieves a significant over 80% reduction in greenhouse gas emissions compared to traditional methods. Through responsible chemistry, reduced water and energy use, sustainable sourcing, and continuous production, Nordic Bioproducts Group aims to set a new standard in microcrystalline cellulose for pharmaceutical and nutraceutical products.
Featuring the world's first continuous production line of up to 10,000 tons of MCC annually, the Lappeenranta factory was designed to ensure the highest level of quality, purity and sustainability in MCC production. Opened in spring 2024, Nordic Bioproducts Group is ramping up production to meet the needs of the pharmaceutical industry.
“We are thrilled to announce the EXCiPACT™ certification for our new Lappeenranta facility,” said Olli Kähkönen, CEO of Nordic Bioproducts Group. “We have designed our facility and processes to ensure quality and purity that not only meet but surpass the rigorous standards set by EXCiPACT™. The certification underscores our dedication to the highest standards in our production processes.”
The certification and audit reports can be reviewed on the EXCiPACT™ website, providing transparency to Nordic Bioproducts Group’s customers.
For additional information:
Minna Laitinen
CCO
Nordic Bioproducts Group
About Nordic Bioproducts Group
Nordic Bioproducts Group Oy (“NBG”), founded in 2019 as a spin-off from Aalto University, stands at the forefront of cellulose innovation, bioproduct development, and commercialization in the Nordics.
At the heart of its mission is a commitment to optimizing the use of renewable natural resources while reducing the world’s dependence on fossil-based resources, fostering circular solutions, and catalyzing impactful change on a global scale.
As a pioneering force, the company is dedicated to introducing breakthrough technologies and biomaterials that redefine the landscape of sustainable solutions.
The company's head office is in Espoo, Finland. More information: nordicbioproducts.fi
